ERBB receptors and cancer: The complexity of targeted inhibitors

Nature Reviews Cancer

Volumn 5, Issue 5, 2005, Pages 341-354

  Hynes, Nancy E ^a   Lane, Heidi A ^b  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMPHIREGULIN; ANASTROZOLE; AROMATASE INHIBITOR; BETACELLULIN; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIREGULIN; ERLOTINIB; EXEL 0999; EXEL 7647; FULVESTRANT; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMATINIB; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MATUZUMAB; MONOCLONAL ANTIBODY; NAVELBINE; NEU DIFFERENTIATION FACTOR; PANITUMUMAB; PELITINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB; ZK 22584;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG PROTEIN BINDING; EPITHELIUM CELL; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 18344390418     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1609     Document Type: Review

References (166)

1. Riese, D. J. & Stern, D. F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20, 41-48 (1998).
2. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
3. Olayioye, M. A., Neve, R. M., Lane, H. A. & Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167 (2000).
4. Schlessinger, J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306, 1506-1507 (2004).
5. Holbro, T. & Hynes, N. E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44, 195-217 (2004).
6. Ramsauer, V. P., Caraway, C. A., Salas, P. J. & Caraway, K. L. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J. Biol. Chem. 278, 30142-30147 (2003).
7. Graus-Porta, D., Beerli, R. R., Daly, J. M. & Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (1997).
8. Yu, H. & Jove, R. The STATs of cancer - new molecular targets come of age. Nature Rev. Cancer 4, 97-105 (2004).
9. Grandis, J. R. et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl Acad. Sci. USA 97, 4227-4232 (2000).
10. Ishizawar, R. & Parsons, S. J. c-Src and cooperating partners in human cancer Cancer Cell 6, 209-214 (2004).
11. Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nature Rev. Cancer 4, 335-348 (2004).
12. Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Rev. Cancer 4, 361-370 (2004).
13. Ohgaki, H. et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 84, 6892-6899 (2004).
14. Sunpaweravong, P. et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 131, 111-119 (2005).
15. Salomon, D. S., Brandt, R., Ciardiello, F. & Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
16. Ekstrand, A. J., Sugawa, N., James, C. D. & Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl Acad. Sci. USA 89, 4309-4313 (1992).
17. Moscatello, D. K. et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55, 5536-5539 (1995).
18. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
19. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
20. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004). References 18-20 are the first reports to describe the presence of cancer-specific mutations in the EGFR kinase domain. Patients with non-small-cell lung tumours containing these mutations had a higher chance of responding to EGFR tyrosine-kinase inhibitors than patients expressing wild-type EGFR in their tumours.
21. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987). This paper was the first to show that ERBB2 gene amplification is associated with an increased risk of relapse and death for patients with early-stage breast cancer.
22. Hynes, N. E. & Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198, 165-184 (1994).
23. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
24. Burgess, A. W. et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12, 541-552 (2003).
25. Garrett, T. P. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 110, 763-773 (2002).
26. Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 (2002). References 25 and 26 are the first to show the crystal structure of the EGFR ectodomain in complex with a ligand. Although each ligand simultaneously contacts two binding sites in the ectodomain, the ligand does not span the ectodomain dimer; EGFR dimerization is entirely receptor mediated. In the latter publication, this unique receptor-mediated dimerization was verified by mutagenesis.
27. Cho, H. S. & Leahy, D. J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330-1333 (2002).
28. Ferguson, K. M. et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11, 507-517 (2003).
29. Batra, S. K. et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6, 1251-1259 (1995).
30. Garrett, T. P. et al. The crystal structure of atruncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495-505 (2003).
31. Cho, H. S. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760 (2003).
32. Harris, R. C., Chung, E. & Coffey, R. J. EGF receptor ligands. Exp. Cell Res. 284, 2-13 (2003).
33. Falls, D. L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284, 14-30 (2003).
34. Borrell-Pages, M., Rojo, F., Albanell, J., Baselga, J. & Arribas, J. TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J. 22, 1114-1124 (2003).
35. Daub, H., Weiss, F. U., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557-560 (1996). Treatment of cells with GPCR agonists induces rapid EGFR tyrosine phosphorylation. This has been termed EGFR transactivation and was shown in this paper to result from metalloproteinase activation leading to the cleavage and release of HB-EGF.
36. Prenzel, N. et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-888 (1999).
37. Luttrell, L. M., Daaka, Y. & Lefkowitz, R. J. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11, 177-183 (1999).
38. Izumi, Y. et al. A metalloprotease-disintegrin, MDC9/meltrin-γ/ ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 17, 7260-7272 (1998).
39. Gschwind, A., Hart, S., Fischer, O. M. & Ulrich, A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 22, 2411-2421 (2003).
40. Wakatsuki, S., Kurisaki, T. & Sehara-Fujisawa, A. Lipid rafts identified as locations of ectodomain shedding mediated by Meltrin β/ADAM19. J. Neurochem. 89, 119-123 (2004).
41. Daaka, Y. G proteins in cancer: the prostate cancer paradigm. Sci. STKE 216, re2 (2004).
42. Scher, H. I. et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin. Cancer Res. 1, 545-550 (1995).
43. Civenni, G., Holbro, T. & Hynes, N. E. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transaction in HC11 mammary epithelial cells. EMBO Rep. 4, 166-171 (2003).
44. Razandi, M., Pedram, A., Park, S. T. & Levin, E. R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278, 2701-2712 (2003).
45. Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926-935 (2004).
46. Luttrell, D. K. & Luttrell, L. M. Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene 23, 7969-7978 (2004).
47. Poghosyan, Z. et al. Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. J. Biol. Chem. 277, 4999-5007 (2002).
48. Seals, D. F. & Courtneidge, S. A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17, 7-30 (2003).
49. Bolen, J. B., Veillette, A., Schwartz, A. M., DeSeau, V. & Rosen, N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc. Natl Acad. Sci. USA 84, 2251-2255 (1987).
50. Ottenhoff-Kalff, A. E. et al. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 52, 4773-4778 (1992).
51. Sliwkowski, M. X. et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26, 60-70 (1999). The different mechanisms that have been proposed to contribute to trastuzumab's clinical efficacy are discussed in this paper.
52. Petit, A. M. et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523-1530 (1997).
53. Overholser, J. P., Prewett, M. C., Hooper, A. T., Waksal, H. W. & Hicklin, D. J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89, 74-82 (2000).
54. Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20, 3210-3223 (2000).
55. Motoyama, A. B., Hynes, N. E. & Lane, H. A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62, 3151-3158 (2002). Trastuzumab-treated breast cancer cells escape from the antiproliferative effects of the monoclonal antibody in the presence of ERBB ligands owing to the fact that trastuzumab cannot block the homo/ heterodimerization of other ERBB receptors.
56. Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004).
57. Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727-739 (2002).
58. Baselga, J. et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20, 4292-4302 (2002).
59. Albanell, J. et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin. Oncol. 20, 110-124 (2002).
60. Malik, S. N. et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin. Cancer Res. 9, 2478-2486 (2003).
61. Vanhoefer, U. et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22, 175-184 (2004).
62. Baselga, J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin. Cancer Res. 9, 2389-2390 (2003).
63. Daneshmand, M. et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin. Cancer Res. 9, 2457-2464 (2003).
64. Tabernero, J. et al. A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR. Eur. J. Cancer 38 (Suppl. 7), 69 (2002).
65. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
66. Herbst, R. S., Fukuoka, M. & Baselga, J. Timeline: Gefitinib-a novel targeted approach to treating cancer. Nature Rev. Cancer 4, 956-965 (2004).
67. Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
68. Hudziak, R. M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165-1172 (1989).
69. Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
70. Molina, M. A. et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749 (2001).
71. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
72. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
73. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, 1-11 (2005). This paper describes the identification of acquired mutations in the EGFR kinase domain of cancer patients who have become resistant to gefitinib or erlotinib.
74. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
75. Harries, M. & Smith, I. The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer 9, 75-85 (2002).
76. Agus, D. B. et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127-137 (2002).
77. Franklin, M. C. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317-328 (2004).
78. Jackson, J. G., St Clair, P., Sliwkowski, M. X. & Brattain, M. G. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res. 64, 2601-2609 (2004).
79. Rubin Grandis, J. et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90, 824-832 (1998).
80. Laban, C., Bustin, S. A. & Jenkins, P. J. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab. 14, 28-34 (2003).
81. Adnane, J. et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6, 659-663 (1991).
82. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. & Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst. 93, 1852-1857 (2001). Results in this paper show that activation of the IGF1R in ERBB2-overexpressing breast cancer cells renders initially trastuzumab-sensitive cells resistant to the antibody.
83. Lu, Y., Zi, X. & Pollak, M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334-341 (2004).
84. kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 64, 3981-3986 (2004).
85. Camirand, A., Lu, Y. & Pollak, M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med. Sci. Monit. 8, BR521-BR526 (2002).
86. Janmaat, M. L., Kruyt, F. A., Rodriguez, J. A. & Giaccone, G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 9, 2316-2326 (2003).
87. She, Q. B., Solit, D., Basso, A. & Moasser, M. M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 9, 4340-4346 (2003).
88. Bianco, R. et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 2812-2822 (2003). This paper shows that tumour cells with low FTEN levels are resistance to ERBB-targeted inhibitors.
89. Eng, C. PTEN: one gene, many syndromes. Hum. Mutat. 22, 183-198 (2003).
90. Thompson, J. E. & Thompson, C. B. Putting the rap on Akt J. Clin. Oncol. 22, 4217-44226 (2004).
91. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
92. Krymskaya, V. P. Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal. 15, 729-739 (2003).
93. Dutcher, J. P. Mammalian target of rapamycin (mTOR) inhibitors. Curr. Oncol. Rep. 6, 111-115 (2004).
94. Koziczak, M. & Hynes, N. E. Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J. Biol. Chem. 279, 50004-50011 (2004).
95. Zhou, X. et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin. Cancer Res. 10, 6779-6788 (2004).
96. Aoki, M., Blazek, E. & Vogt, P. K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl Acad. Sci. USA 198, 136-1341 (2001). Results presented in this paper justify combining mTOR inhibitors with inhibitors blocking other signalling entities such as the ERBB receptors, as the data demonstrate that cellular transformation can be independently driven by non-overlapping signalling pathways.
97. Venkateswarlu, S. et al. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 21, 78-86 (2002).
98. Stal, O. et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 5, R37-R44 (2003).
99. Clark, A. S., West, K., Streicher, S. & Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1, 707-717 (2002).
100. Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Med. 10, 594-801 (2004).
101. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001). This paper shows that PTEN-deficient tumour cells are particularly sensitive to mTOR inhibition. These results are important because they indicate that activation of the PI3K pathway could affect response to mTOR inhibition.
102. Doisneau-Sixou, S. F. et al. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 10, 179-186 (2003).
103. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trias involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339, 1-15 (1992).
104. Robertson, J. F. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat. Rev. 30, 695-706 (2004).
105. Smith, I. E. & Dowsett, M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431-2442 (2003).
106. Schiff, R. et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10, 331S-336S (2004).
107. Matsuda, S. et al. 17β-estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc. Natl Acad. Sci. USA 90, 10803-10807 (1993).
108. Ellis, M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9 (Suppl. 3), 20-26 (2004).
109. Gee, J. M. et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144, 5105-5117 (2003).
110. Chung, Y. L., Sheu, M. L., Yang, S. C., Lin, C. H. & Yen, S. H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int. J. Cancer 97, 306-312 (2002).
111. Keshamouni, V. G., Mattingly, R. R. & Reddy, K. B. Mechanism of 17-β-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-δ. J. Biol. Cnem. 277, 22558-22565 (2002).
112. Simoncini, T. et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538-541 (2000).
113. Ali, S. & Coombes, R. C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev. Cancer 2, 101-112 (2002).
114. Martin, L. A. et al. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. 278, 30458-30468 (2003).
115. Dowsett, M. et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 61 8452-8458 (2001).
116. Dowsett, M. Molecular changes in tamoxifen-relapsed breast cancer: relationship between ER, HER2 and p38-MAP-kinase. Proc. Am. Soc. Clin. Oncol. 22, 3 (2003).
117. Arpino, G. et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res. 10, 5670-5676 (2004).
118. De Placido, S. et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin. Cancer Res. 9, 1039-1046 (2003).
119. Elis, M. J. et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19, 3808-3816 (2001). This clinical study revealed that patients with EGFR-or ERBB2-positive breast tumours responded well to the aromatase Inhibitor letrozole but poorly to the SERM tamoxifen. These results demonstrate the value of molecular profiling to aid the selection of appropriate targeted therapies.
120. Ropero, S. et al. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res. Treat. 86, 125-137 (2004).
121. Aboud-Pirak, E. et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl Cancer Inst. 80, 1605-1611 (1988).
122. Pietras, R. J. et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9, 1829-1838 (1994). This paper provides a mechanism of the synergistic activity of trastuzumab and cisplatin in ERBB2-overexpressing cancer cells. Downregulation of ERBB2 signalling activity interferes with the ability of cancer cells to repair DNA adducts, leading to death of tumour cells.
123. Pegram, M. D., Lopez, A., Konecny, G. & Slamon, D. J. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol. 27, 21-25 (2000).
124. Pegram, M. D. et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer Inst. 96, 739-749 (2004).
125. Pegram, M. D. et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl Cancer Inst. 96, 759-769 (2004).
126. Ciardiello, F. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053-2063 (2000).
127. Dancey, J. E. Predictive factors for epidermal growth factor receptor inhibitors - the bull's-eye hits the arrow. Cancer Cell 5, 411-415 (2004).
128. Holbro, T. et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA 100, 8933-8938 (2003). This paper uses elegant technology to demonstrate that ERBB2-overexpressing breast cancer cells use ERBB3 to activate the PI3K pathway. Both downregulation of ERBB3 expression and targeting ERBB2 directly with TKIs block proliferation of tumour cells.
129. Mitsiades, C. S. et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5, 221-230 (2004).
130. Ward, S. G. & Finan, P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3, 426-434 (2003).
131. Mills, G. B. et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer, Semin. Oncol. 30, 93-104 (2003).
132. Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev. Cancer 4, 937-947 (2004).
133. Dibb, N. J., Dilworth, S. M. & Mol, C. D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family Nature Rev. Cancer 4, 718-727 (2004).
134. Wood, J. M. et al. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178-2189 (2000).
135. Shaheen, R. M. et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer 85, 584-589 (2001).
136. Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931-4941 (2004). This paper presents an extensive in vitro and in vivo analysis of the activity of the multifunction inhibitor AEE788, which targets both ERBB and VEGFRs. A direct comparison with ERBB- and VEGFR-specific TKIs used in combination is performed.
137. Jorissen, R. N. et al. Epidermal growth factor receptor: mechanisms of activation and signalling, Exp. Cell Res. 284, 31-53 (2003).
138. Dankort, D., Jeyabalan, N., Jones, N., Dumont, D. J. & Muller, W. J. Multiple ErbB-2/Neuphosphorylation sites mediate transformation through distinct effector proteins. J. Biol. Chem. 276, 38921-38928 (2001).
139. Marone, R. et al. Memo mediates ErbB2-driven cell motility. Nature Cell Biol. 6, 515-522 (2004).
140. Kim, H. H., Vijapurkar, U., Hellyer, N. J., Bravo, D. & Koland, J. G. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem. J. 334 (Pt 1), 189-195 (1998).
141. Yen, L. et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol. Biol. Cell 13, 4029-4044 (2002).
142. Baker, C. H. et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am. J Pathol. 161, 929-938 (2002).
143. Heimberger, A. B. et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin. Cancer Res. 8, 3496-3502 (2002).
144. Kip1 at threonine 157 and modulation of its cellular localization. Nature Med. 8, 1145-1152 (2002).
145. Miettinen, P. J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor Nature 376, 337-341 (1995).
146. Sibilia, M. & Wagner, E. F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269, 234-238 (1995).
147. Threadgill, D. W. et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230-234 (1995).
148. Tan, A. R. et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with ertotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J . Clin. Oncol. 22, 3080-3090 (2004).
149. Cohen, E. E. et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21, 1980-1987 (2003).
150. Camus, P., Kudoh, S. & Ebina, M. Interstitial lung disease associated with drug therapy. Br. J. Cancer 91 (Suppl. 2), S18-S23 (2004).
151. Sumpter, K., Harper-Wynne, C., O'Brien, M. & Congleton, J. Severe acute interstitial pnuemonia and gefitinib. Lung Cancer 43, 367-368 (2004).
152. Suzuki, H., Aoshiba, K., Yokohori, N. & Nagai, A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 63, 5054-5059 (2003).
153. Lee, K. F. et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398 (1995).
154. Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 8, 459-465 (2002).
155. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
156. Gassmann, M. et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390-394 (1995).
157. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386-390 (1995).
158. Fuchs, I. B. et al. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res. Treat. 82, 23-28 (2003).
159. Zhao, Y. Y. et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 273, 10261-10269 (1998).
160. Sato, J. D. et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1, 511-529 (1983).
161. Schreiber, A. B., Lax, I., Yarden, Y., Eshhar, Z. & Schlessinger, J. Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc. Natl Acad. Sci. USA 78, 7535-7539 (1981).
162. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P. & Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1, 1311-1318 (1995).
163. Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285-4289 (1992).
164. Honegger, A. M. et al. A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis. Mol. Cell. Biol. 7, 4568-4571 (1987).
165. Traxler, P. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin. Ther. Targets 7, 215-234 (2003).
166. Gazit, A., Yaish, P., Gilon, C. & Levitzki, A. Tyrphostins I: synthesis and bioiogical activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32, 2344-2352 (1989).